JRCT ID: jRCT1061210049
Registered date:12/11/2021
Survey on the SARS-CoV-2 additional vaccination
Basic Information
| Recruitment status | Not Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Severe acute respiratory syndrome coronavirus 2 |
| Date of first enrollment | 15/11/2021 |
| Target sample size | 1500 |
| Countries of recruitment | |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Transition of SARS-CoV-2 serum antibody titer after the SARS-CoV-2 additional vaccination |
|---|---|
| Secondary Outcome | Transition ofHealth condition after the SARS-CoV-2 additional vaccination Backgroud factor that is contribute transition of SARS-CoV-2 serum antibody titer |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Both |
| Include criteria | School staff who are participating in jRCT1061200057 research and receive the additional SARS-CoV-2 vaccination in December 2021 |
| Exclude criteria | None |
Related Information
| Primary Sponsor | Nakano Takashi |
|---|---|
| Secondary Sponsor | Ohira Shin |
| Source(s) of Monetary Support | Health and Labor Administration Promotion Research Project subsidy,School research expenses |
| Secondary ID(s) |
Contact
| Public contact | |
| Name | Shin Ohira |
| Address | 577 Mastushima, Kurashiki city, Okayama prefecture Okayama Japan 701-0192 |
| Telephone | +81-86-462-1111 |
| ohira@med.kawasaki-m.ac.jp | |
| Affiliation | Kawasaki Medical School Hospital |
| Scientific contact | |
| Name | Takashi Nakano |
| Address | 2-6-1 Nakasange, Kita-ku, Okayama city, Okayama prefecture Okayama Japan 700-8505 |
| Telephone | +81-86-225-2111 |
| nakano@med.kawasaki-m.ac.jp | |
| Affiliation | Kawasaki Medical School General Medical Center |